Inotek Commences Phase 1 Trial In Glaucoma With Selective Adenosine 1 (A1) Agonist
Inotek Pharmaceuticals Corporation announced that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients.
Doctors Of Optometry Urge Contact Lens Wearers To Be Vigilant With Lens Hygiene And Compliance In Flood Areas
As flooding continues to expand across much of the Midwest, the American Optometric Association (AOA) reminds contact lens wearers to closely follow hygiene and compliance instructions issued by their eye doctor. Higher temperatures combined with standing water can mean an increase in the number of cases of eye infections. In particular, the Acanthamoeba parasite and other micro-organisms can contaminate the lens case and infect the cornea.
Allergan Receives U.S. Food And Drug Administration Approval For TRIVARIS? (triamcinolone Acetonide Injectable Suspension) 80 Mg/mL
Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved TRIVARIS? (triamcinolone acetonide injectable suspension) 80 mg/mL, a synthetic glucocorticoid corticosteroid with anti-inflammatory action. Delivered via intravitreal injection, the ophthalmic indications for TRIVARIS? include sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.In a study published in a recent edition of the Journal of Clinical Pathology, Geisinger researchers examined a disorder known as temporal arteritis. In this disease, arteries swell and restrict blood flow to the brain.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care. In the first project, researchers from the Centre for Reviews and Dissemination at the University of York are set to investigate colour vision testing, which can be used to help identify patients at risk of diabetic retinopathy.
IOPtima Successfully Completes Initial Clinical Study For Glaucoma Using Novel Laser-Based Therapy
IOPtima, a subsidiary of Bio-Light Life Science Investments (TASE:BOLT), announced that it has successfully completed the 3 month follow-up period for an initial human clinical study using the company's OT134 device and procedure. The novel, laser-based therapy enables eye surgeons to operate and reduce internal eye pressure without penetrating the eye membrane.
Corneal Inflammation Inhibited By Case Western Reserve And Penn State Investigators
Researchers from the Case Western Reserve University School of Medicine and Penn State Hershey College of Medicine identified a novel therapeutic that reduces sterile inflammation within the cornea. Published in the June issue of the Journal of Leukocyte Biology, Dr. Eric Pearlman and Dr. Mark Kester identified a novel ceramide, a natural compound that when delivered in nano-sized packages reduces corneal haze, corneal thickening and inflammation.
National Glaucoma Awareness Week: 9th - 15th June 2008
Are you over 40? Is glaucoma in your family? Are you African-Caribbean? Are you short sighted? Do you have diabetes? If the answer is yes to any of these questions, you definitely should have your eyes tested regularly. Primary open angle glaucoma (POAG) has no symptoms, but slowly and painlessly it destroys sight if it is not detected and treated. The loss of vision cannot be reversed.
The diabetes medication rosiglitazone has been associated with areduction in the likelihood of developing the eye disease calledproliferative diabetic retinopathy. A study published in the June issueof Archives of Ophthalmology also found thatdiabetes patients using the drug were less likely to have reductions invisual acuity (or sharpness).
New AllAboutVision.com Content Provides Great Tips For Summer Eye Safety
From sun-related eye damage to sports-related eye injuries to sometimes blinding accidents caused by Fourth of July fireworks, summer can be hazardous to eye health. But to enjoy summer activities safely, you need only observe a few common-sense precautions, such as wearing appropriate safety eyewear to help protect your and your family's precious eyesight.
Omega-3 Fatty Acids Linked To Prevention Of Macular Degeneration
Researchers have more good news for those who enjoy eating fish. Ameta-analysis published in the June issue of Archives ofOphthalmology found that consumption of foods high in omega-3fatty acids, such as fish and flax, is linked to a reductionin the risk of age-related macular degeneration (AMD) - a common eyedisease. However, the authors indicate a need for more clinical trialsbefore they can advocate routineconsumption of these foods for the prevention of AMD.
Protect Your Eyes And Attend Professional Fireworks Displays
This year for the 4th of July celebrations, the American Optometric Association (AOA) suggests that families and friends stay away from private firework use and instead enjoy professional displays to protect and preserve eyesight. Each year over the holiday, thousands of adults and children are seriously injured as a result of fireworks and pyrotechnic devices. Many burns and injuries affect eyesight, permanently damaging and in some cases blinding the victims.
Akorn, Inc. Receives NDA Approvable Letter For Akten(R) Ophthalmic Gel 3.5%
Akorn, Inc. (NASDAQ: AKRX) announced the receipt of an FDA approvable letter for Akten® Ophthalmic Gel 3.5%, an ocular topical anesthetic drug product. Our approvable letter identified several minor CMC deficiencies that must be addressed and rectified before final approval is granted. The majority of these items have been addressed in our previous submissions to the FDA. The remaining response will be submitted to the FDA within the next ten days.
A new Centre for Eye Research Australia/ Access Economics report shows the cost of glaucoma will more than double in the next two decades.'Tunnel Vision: the Economic Impact of Primary Open Angle Glaucoma', shows associated healthcare costs totaled $1.9 billion in 2005 and costs are expected to climb to $4.3 billion per annum by 2025, if no changes are made to current practices.
Acucela Doses First Subject In Phase I Trial For Age-Related Macular Degeneration
Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has dosed the first subject in a Phase I trial for its lead compound ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.
JAYPEE HIGHLIGHTS MEDICAL PUBLISHERS, INC. at: e-mail: cservice@jphmedical.com TEL: From U.S.A 011-507-317-0160, Out U.S.A 00-507-317-0161 ~ FAX: From U.S.A 011-507-317-0155, Out U.S.A 00-507-317-0161 P.O. Box 0818-00848; El Dorado,
Republic of Panama
